Literature DB >> 23398196

The epidemiology of intermittent and chronic ataxia in children in Manitoba, Canada.

Michael S Salman1, Esther J Lee, Anindita Tjahjadi, Bernard N Chodirker.   

Abstract

AIM: To determine the epidemiology of chronic ataxia in children in Manitoba, Canada.
METHOD: A retrospective study using multiple sources and disease codes identified children (age 0-16y) with chronic ataxia (>2mo duration or recurrent episodes of ataxia) seen at Winnipeg Children's Hospital from 1991 to 2008. Patients with isolated peripheral nerve diseases, vestibular disorders, or brain tumors were excluded.
RESULTS: We identified 184 patients (males=females; mean age 15y, SD 7y 8mo) with chronic ataxia. Median age at the presenting symptom onset was 1 year 3 months and at ataxia onset 3 years 1 month. Median duration of follow-up was 6 years 5 months. During the study period, the crude incidence rate was 5.77 in 10,000; the crude prevalence rate was 6.59 in 10,000; and the crude mortality rate 0.446 in 10,000. The most common presenting symptoms were developmental delay, ataxia, or seizures. The most common diagnoses (known in 129) were Angelman syndrome (n=16), ataxia telangiectasia (n=13), mitochondrial disease (n=9), Friedreich ataxia (n=7), stroke (n=7), and familial/genetic episodic ataxia (n=7).
INTERPRETATION: Chronic ataxia is a relatively common early-presenting symptom in childhood. A specific diagnosis is possible in 70% of patients after extensive investigations. The mortality rate is relatively low and the disease burden is high with significant comorbidities including developmental delay and epilepsy. © The Authors. Developmental Medicine & Child Neurology
© 2013 Mac Keith Press.

Entities:  

Mesh:

Year:  2013        PMID: 23398196     DOI: 10.1111/dmcn.12081

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

1.  Can Latent Class Analysis Be Used to Improve the Diagnostic Process in Pediatric Patients with Chronic Ataxia?

Authors:  Samantha Klassen; Brenden Dufault; Michael S Salman
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

2.  Dopa-Responsive Dystonia and Chorea as a Presenting Feature in Ataxia-Telangiectasia.

Authors:  Sarah Thompson; Anand Iyer; Philip Byrd; Malcolm Taylor; Stefan Spinty
Journal:  Mov Disord Clin Pract       Date:  2014-06-11

3.  Neuro-Ophthalmological Findings in Children and Adolescents with Chronic Ataxia.

Authors:  Michael S Salman; Bernard N Chodirker
Journal:  Neuroophthalmology       Date:  2015-06-17

Review 4.  Epidemiology of Cerebellar Diseases and Therapeutic Approaches.

Authors:  Michael S Salman
Journal:  Cerebellum       Date:  2018-02       Impact factor: 3.847

5.  Genetic and Clinical Predictors of Ataxia in Pediatric Primary Mitochondrial Disorders.

Authors:  Juan Sebastian Martin-Saavedra; Sara Reis Teixeira; Cesar Augusto Pinheiro Ferreira Alves; Fabrício Guimarães Gonçalves; Luis Octavio Tierradentro-García; Martin Kidd; Colleen Muraresku; Amy Goldstein; Arastoo Vossough
Journal:  Cerebellum       Date:  2021-05-30       Impact factor: 3.847

Review 6.  Ataxia in Childhood: Epidemiological, Clinical and Neuroradiologic Features, and the Risk of Recurrence.

Authors:  Mohsen Javadzadeh; Masoud Hassanvand Amouzadeh; Shaghayegh Sadat Esmail Nejad; Ezatollah Abasi; Abbas Alipour; Mohsen Mollamohammadi
Journal:  Iran J Child Neurol       Date:  2017

Review 7.  Degenerative Ataxias: challenges in clinical research.

Authors:  Sub H Subramony
Journal:  Ann Clin Transl Neurol       Date:  2016-11-17       Impact factor: 4.511

8.  A simple saccadic reading test to assess ocular motor function in cerebellar ataxia.

Authors:  Angela Jinsook Oh; Tiffany Chen; Mohammad Ali Shariati; Naz Jehangir; Thomas N Hwang; Yaping Joyce Liao
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

9.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.